Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details) - USD ($) $ in Millions				12 Months Ended
	Jul. 01, 2022	Jun. 30, 2022	Apr. 01, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
One-time payment				$ (56.9)
Revenues				$ 12,172.9	$ 16,071.7	$ 8,497.1
Sanofi Collaboration Agreement, Antibody
Disaggregation of Revenue [Line Items]
Percentage of quarterly profits require to be paid for reimbursement of development costs				10.00%
Percentage of share of profits used to reimburse collaborating party for trial costs	20.00%	10.00%
Contingent reimbursement obligation				$ 2,864.0
Starting share of profits outside the United States, based on sales, for collaborating party				65.00%
Starting share of profits outside the United States, based on sales, for company				35.00%
Ending share of profits outside the United States, based on sales, for collaborating party				55.00%
Ending share of profits outside the United States, based on sales, for company				45.00%
Share of losses outside the United States, for collaborating party				55.00%
Share of losses outside the United States, for company				45.00%
Sanofi Collaboration Agreement, Antibody | First Milestone
Disaggregation of Revenue [Line Items]
Levels of twelve month sales at which sales milestone payments would be received						$ 1,000.0
Sanofi Collaboration Agreement, Antibody | Second Milestone
Disaggregation of Revenue [Line Items]
Levels of twelve month sales at which sales milestone payments would be received					$ 1,500.0
Period for achieving sales target for milestone payment, rolling basis					12 months
Sanofi Collaboration Agreement, Antibody | Third Milestone
Disaggregation of Revenue [Line Items]
Revenues				$ 50.0
Levels of twelve month sales at which sales milestone payments would be received				2,000.0
Sanofi Collaboration Agreement, Antibody | Sales Milestone Four
Disaggregation of Revenue [Line Items]
Levels of twelve month sales at which sales milestone payments would be received				$ 2,500.0
Period for achieving sales target for milestone payment, rolling basis				12 months
Sanofi Collaboration Agreement, Antibody | Sales Milestone Five
Disaggregation of Revenue [Line Items]
Levels of twelve month sales at which sales milestone payments would be received				$ 3,000.0
Period for achieving sales target for milestone payment, rolling basis				12 months
Revenue, remaining performance obligation, variable consideration amount				$ 50.0
Sanofi Collaboration Agreement, Antibody | Minimum
Disaggregation of Revenue [Line Items]
Percentage of trial costs required to be funded by collaborating party				80.00%
Percentage of quarterly profits require to be paid for reimbursement of development costs				30.00%
Sanofi Collaboration Agreement, Antibody | Maximum
Disaggregation of Revenue [Line Items]
Percentage of trial costs required to be funded by collaborating party				100.00%
Percentage of quarterly profits require to be paid for reimbursement of development costs				50.00%
Praluent Agreement
Disaggregation of Revenue [Line Items]
Royalty percentage to be received on net product sales outside of the United States			5.00%
Percentage of damages company is responsible for			50.00%
Praluent Agreement | Sanofi
Disaggregation of Revenue [Line Items]
Percentage of royalty payment that can be used to offset litigation proceedings			50.00%